MARLBOROUGH, Mass. (AP) — MARLBOROUGH, Mass. (AP) — Akoya Biosciences Inc. (AKYA) on Monday reported a loss of $8.2 million in its fourth quarter. On a per-share basis, the Marlborough, ...

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.22 per share a year ago. These figures ...

Reports Q4 revenue $21.3M, consensus $21.34M. Gross margin was 67.4% in the fourth quarter of 2024, compared to 62.7% in the prior year ...

Quanterix issued the following statement: Quanterix’s proposed acquisition of Akoya is the result of a rigorous and thorough Board evaluation consistent with its commitment to position the Company for ...

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single ...

Akoya Biosciences announced a significant expansion of its product offerings with the introduction of new high-plex neurobiology panels for human and mouse applications, enhancing their recent ...

Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and ...

Akoya, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $18.81 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 25.39% ...

Quanterix issued the following statement: Quanterix’s proposed acquisition of Akoya is the result of a rigorous and thorough Board evaluation consistent with its commitment to position the ...